Liquid Biopsy Consortium

Featured Infographic

Liquid Biopsy: A new, noninvasive technique that can detect disease biomarkers in blood, urine, and sputum.

In the era of personalized medicine, having minimally invasive methods to determine and follow the molecular composition and characterization of a patient’s tumor over time will help gain a broader understanding of the disease. One such approach is liquid biopsy : measurements to characterize the molecular level of the tumor and monitor genetic changes over time using repeat sampling of biofluids. Liquid biopsy generally refers to detecting and measuring circulating tumor cells (CTC), circulating tumor DNA (ctDNA), circulating exosomes and other analytes in body fluids, such as serum, plasma, urine, etc.

About the Liquid Biopsy Consortium

The Liquid Biopsy Consortium is an Academic/Industrial Partnership program designed to advance and validate Liquid Biopsy technologies specifically targeted for early stage cancer detection. The goal is to test body fluids such as blood, urine, saliva, stool, and sputum from patients suspected to have early stage cancer as well as those at high risk of developing cancer. The Liquid Biopsy Consortium is also working on methods to distinguish cancer from benign disease; or aggressive from indolent cancers. Projects from funded sites focus on the development of new tools/methods/assays and/or validations of existing technologies/methods involving the capture of DNA, RNA, or exosomes in circulating body fluids.

Funding Opportunity

No matching Funding Opportunities were found.

View All Funding Opportunities

Grantee Details

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Smith, Ellen Mary Lavoie	University Of Alabama At Birmingham United States	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study	5R01CA235726-07	Brennan Streck, Ph.D., RN, M.P.H.
Smith, Ellen Mary Lavoie	University Of Alabama At Birmingham United States	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study	5R01CA235726-07	Brennan Streck, Ph.D., RN, M.P.H.
Smith, Jennifer Susan	Univ Of North Carolina Chapel Hill United States	UNC CASCADE Network Research Base	5UG1CA275403-04	Maria Silvina Frech, Ph.D., M.S.
Sohl, Stephanie Jean	Wake Forest University Health Sciences United States	REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE)	5R01CA266995-04	Goli Samimi, Ph.D., M.P.H.
Sohl, Stephanie Jean	Wake Forest University Health Sciences United States	REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE)	5R01CA266995-04	Goli Samimi, Ph.D., M.P.H.
Somers, Tamara J	Duke University United States	A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial	5R01CA237892-05	Brennan Streck, Ph.D., RN, M.P.H.
Somers, Tamara J	Duke University United States	A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial	5R01CA237892-05	Brennan Streck, Ph.D., RN, M.P.H.
Song, Ming	University Of Louisville United States	Dietary fructose and NASH/HCC progression	5R21CA290420-02	Amit Kumar, Ph.D.
Sorror, Mohamed	Fred Hutchinson Cancer Center United States	Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality	5R01CA227092-06	Marjorie Perloff, M.D.
Sorror, Mohamed	Fred Hutchinson Cancer Center United States	Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality	5R01CA227092-06	Marjorie Perloff, M.D.
Sorror, Mohamed	Fred Hutchinson Cancer Center United States	Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality	5R01CA227092-06	Marjorie Perloff, M.D.
Spector, Tim	King'S College London United States	PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	1OT2CA297289-01	Asad Umar, D.V.M., Ph.D.
Spiegel, Brennan	Cedars-Sinai Medical Center United States	Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	5R01CA252211-05	Rachel Altshuler, Ph.D.
Spiegel, Brennan	Cedars-Sinai Medical Center United States	Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	5R01CA252211-05	Rachel Altshuler, Ph.D.
Stachler, Matthew D	University Of California, San Francisco United States	Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagus	3R37CA269649-03S1	Matthew Young, Ph.D.

Program Contact(s)

Sudhir Srivastava, Ph.D., M.P.H.
Email: sudhir.srivastava@nih.gov

Christos Patriotis, Ph.D.
Email: christos.patriotis@nih.gov

Nicholas A. Hodges, Ph.D.
Email: nick.hodges@nih.gov

Guillermo Marquez, Ph.D.
Email: guillermo.marquez@nih.gov